Use of Verapamil and Dilthiasem in treating patients at high cardiovascular risk (review of literature)
Abstract
The article deals with usage of nondihydropiridine calcium antagonists - verapamil and dilthiasem - in treating patients with arterial hypertension, cardiomyopathy and arrhythmia, for secondary prevention of IHD. Data also concern cardio-, angio - and nephroprotective activity of the medications, their ability to prevent left ventricle hypertrophy, possible usage in patients after myocardial infarction. The authors also discuss problems of tolerance and safety of calcium antagonists with prolonged action vs. those with short-term action.
Keywords
верапамил,
дилтиазем,
антагонисты кальция,
недигидропиридиновые антагонисты кальция,
артериальная гипертония,
стенокардия,
антагонисты кальция пролонгированного действия,
verapamil,
dilthiasem,
calcium antagonists,
nondihydropiridine calcium antagonists,
arterial hypertension,
stenocardia,
calcium antagonists with prolonged action
About the Authors
G. A. Baryshnikova
Central state medical academy of department of presidential affairs of the Russian Federation
Россия
Россия
S. A. Chorbinskaya
Central state medical academy of department of presidential affairs of the Russian Federation
Россия
Россия
I. I. Stepanova
Central state medical academy of department of presidential affairs of the Russian Federation
Россия
Россия
O. E. Blokhina
Central state medical academy of department of presidential affairs of the Russian Federation
Россия
Россия
I. V. Zverkov
Central state medical academy of department of presidential affairs of the Russian Federation
Россия
Россия
L. V. Maslovskyi
Central state medical academy of department of presidential affairs of the Russian Federation
Россия
Россия
N. B. Korchazhkina
The main medical administration of the Department of presidential Affairs of the Russian Federation
Россия
Россия
O. M. Maslennikova
Central state medical academy of department of presidential affairs of the Russian Federation
Россия
Россия
References
1. Рекомендации РМОАГ/ВНОК по диагностике и лечению артериальной гипертонии (IV пересмотр), 2010
2. Boden W.E., van Gilst W.H., Scheldewaert R.G. et al. // Lancet. - 2000. - № 355 (9217). - p. 1751-1756.
3. Gibson R.S., Boden W.E., Therous P. et al. // N. Engl. J. Med. - 1986. - № 315. - p. 423-9.
4. Goldstein R.E., Boccuzzi S.J., Cruess D. et al. // Circulation. - 1991. - V. 83. - p. 52-60.
5. Grossman E., Messerli F.H. // Progress in Cardiovascular. - Dis. 2004. - V. 47 (1). - p. 34-57.
6. Hricik D.E., Levine B.S., Adrogue H.J. et al. // J. Hum. Hypertens. - 1996. - V. 10 (11). - p. 769-774.
7. Multicenter DiltiazemPostinfarction Trial Research Group. // N. Engl. J. Med. - 1988. - V. 319. - p. 385-392.
8. Moss A.J., Oakes D., Rubison M. et al. // Am. J. Cardiol. - 1991. - V. 68. - p. 429-433.
9. Nadeau C., Hilton D., Savard D. et al. //Am. J. Cardiol. - 1995. - V. 75. - p. 555-558.
10. Pérez-Maraver M. 1., Carrera M.J., Micaló T. et al. // Diabetes Res. Clin. Pract. - 2005. - V. 70 (1). - p. 13-19.
11. Toyo-Oka T., Nayler W.G. // Blood Pressure. - 1996. suppl. - p. 206-208.
12. Weiss R.J., Bent B. // J. Clin. Hypertens. - 1987. - V. 3 (2). - p. 135-143.
Review
For citations:
Baryshnikova G.A., Chorbinskaya S.A., Stepanova I.I., Blokhina O.E., Zverkov I.V., Maslovskyi L.V., Korchazhkina N.B., Maslennikova O.M. Use of Verapamil and Dilthiasem in treating patients at high cardiovascular risk (review of literature). Russian Journal of Occupational Health and Industrial Ecology. 2016;(2):15-17. (In Russ.)
Views:
1057
JATS XML
Email this article 
